About 50% of people who take the drug infliximab for inflammatory bowel diseases, such as Crohn’s disease, end up becoming resistant or unresponsive to it. Scientists might be able to catch problems ...
About 50% of people who take the drug infliximab for inflammatory bowel diseases, such as Crohn's disease, end up becoming resistant or unresponsive to it. Scientists might be able to catch problems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results